estimates, target lowered at UBS. Shares of RDC now seen reaching $41, according to UBS. Estimates also lowered on higher operating and interest expenses. Buy rating.
Rowan Companies numbers lowered at Jefferies. Shares of RDC now seen reaching $45, Jefferies said. Estimates also lowered on disappointing guidance. Buy rating.
target lowered at Jefferies tO $93, Jefferies said. Plans provide visibility into vast probables value but main challenge is managing cash flows. Buy rating.
numbers raised at Credit Suisse. Shares of THC now seen reaching $7, according to Credit Suisse. Estimates also increased, as growth should accelerate in the second half of the year. Outperform rating.
numbers increased at BofA/Merrill through 2014, Bank of America/Merrill Lynch said. Demand has been solid and the company is buying back more shares. Buy rating and new $95 price target.
target raised at Oppenheimer to $34, Oppenheimer said. Addition of Buccolam to net present value. Outperform rating.
ViroPharma Incorporated numbers raised at Jefferies. Shares of VPHM now seen reaching $37, Jefferies said. Estimates also raised on expanded manufacturing capacity. Buy rating.
>To submit a news tip, email:
and become a fan on